De-novo and acquired resistance to immune checkpoint targeting
Top Cited Papers
- 1 December 2017
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (12), e731-e741
- https://doi.org/10.1016/s1470-2045(17)30607-1
Abstract
No abstract availableKeywords
This publication has 107 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeditingNature, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaThe New England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem CellsCancer Research, 2009
- Inhibitory effect of tumor cell–derived lactic acid on human T cellsBlood, 2007
- Bystander elimination of antigen loss variants in established tumorsNature Medicine, 2004
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996